Dajia Weikang Co., Ltd.

Legal Opinion from Hunan Qiyuan Law Firm on the 2025 Annual Shareholders' Meeting of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Announcement on the completion of the cancellation of certain stock options under the 2023 restricted stock and stock option incentive plan

Announcement on holding the 2025 annual and first quarter online performance briefing

Notice of the 2025 Annual Shareholders' Meeting

Announcement on the Renewal of the Accounting Firm

Announcement on the Compensation Plan for Directors and Senior Management for the Year 2026

Board of Directors Work Report for 2025

Independent Director Work Report for 2025 (Liu Shuping)

Independent Director Work Report for 2025 (Wang Zhigang)

Independent Director Work Report for 2025 (Chen Hao)

Independent Director Work Report for 2025 (Tang Zhi)

Internal Control Audit Report

Internal Control Evaluation Report for 2025

Compensation Management System for Directors and Senior Management

Announcement on the Provision for Credit Impairment and Asset Impairment for the Year 2025

Legal Opinion Letter from Hunan Qiyuan Law Firm on the Adjustment of Prices, Cancellation of Restricted Stocks, and Cancellation of Stock Options Related to the 2023 Restricted Stock and Stock Option Incentive Plan of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.

Announcement on the Cancellation of Certain Class II Restricted Stocks and Stock Options under the 2023 Restricted Stock and Stock Option Incentive Plan

Special Report on the Annual Storage, Management, and Use of Raised Funds for 2025

Announcement on the Estimated Guarantee Limit for the Year 2026

Announcement of the Resolutions of the 19th Meeting of the 4th Board of Directors

Announcement on Proposing the Shareholders' Meeting to Authorize the Board of Directors to Formulate and Implement the Mid-Term Dividend Plan for 2026

Announcement on the Proposal Not to Distribute Profits for the Year 2025

Quarterly Report for Q1 2026

Verification Opinion of Guojin Securities Co., Ltd. on the Annual Storage, Management, and Use of Raised Funds of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd. for 2025

Verification Report on the Annual Storage, Management, and Use of Raised Funds

Special Verification Opinion on the Deduction of Operating Income

Report of the Audit Committee of the Board of Directors on the Evaluation of the Performance of the Accounting Firm for the Year 2025 and the Fulfillment of Supervisory Responsibilities

Special Audit Explanation on Non-Operating Fund Occupation and Other Related Fund Transactions

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for the Year 2025

Special Report of the Board of Directors on the Self-Examination of the Independence of Independent Directors

2025 Annual Audit Report

2025 Annual Report

Summary of the 2025 Annual Report

Articles of Association of Hunan Dajia Weikang Pharmaceutical Industry Co., Ltd.

Announcement on the proposed change of company name, revision of the Articles of Association, and handling of industrial and commercial change registration

Announcement on the adjustment of the relevant prices of the 2023 restricted stock and stock option incentive plan

Announcement on the progress of external guarantees

Announcement on the progress of external guarantees

Progress Announcement on External Guarantees

Progress Announcement on External Guarantees

Progress Announcement on External Guarantees